The most frequent mutation is the point mutation of the Janus kinase 2 (JAK2) gene (JAK2V617F) that can be observed in most patients with PV (95%), ET (50%), and PMF (60%) [116,117,118,119]. This evidence concerns the gene JAK2 and essential thrombocythemia.